PURPOSE: Fatigue and disrupted sleep often coexist and both are prominent clinical problems in cancer affecting quality of life. Disrupted sleep patterns are likely related to cancer-related fatigue. The relationship needs further investigation. This study aimed to characterize and compare disrupted sleep patterns in fatigued breast cancer patients receiving chemotherapy with postmenopausal women without a history of cancer. Anxiety levels were also examined. METHODS: Data for this secondary analysis came from two studies. Global sleep quality and state anxiety were self-reported by 30 fatigued female breast cancer chemotherapy outpatients and 32 non-cancer postmenopausal women using Pittsburgh Sleep Quality Index (PSQI) and State-Trait Anxiety Inventory, respectively. RESULTS: Fatigued breast cancer patients showed significant sleep difficulties, characterized by prolonged sleep onset latency (M=54.3, SD=49.2 min) and frequent nighttime awakenings, despite 40% of the patients using sleep medications three or more times a week. Compared to the non-cancer comparison group, fatigued patients reported significantly longer sleep latency (p=0.041), more use of sleep medications (p=0.006), and higher total PSQI scores (p=0.005). State anxiety levels did not differ between the two groups (p=0.88). CONCLUSIONS: Sleep is disrupted in fatigued breast cancer women undergoing chemotherapy. Nearly all fatigued patients (97%) had trouble sleeping (global PSQI scores>5), indicating significant difficulties in overall sleep quality among those patients. Knowledge of the nature of sleep disruption among cancer patients may contribute to CRF symptom management leading to tailored interventions designed to improve sleep quality in cancer patients thereby managing fatigue and improving quality of life.
PURPOSE:Fatigue and disrupted sleep often coexist and both are prominent clinical problems in cancer affecting quality of life. Disrupted sleep patterns are likely related to cancer-related fatigue. The relationship needs further investigation. This study aimed to characterize and compare disrupted sleep patterns in fatigued breast cancerpatients receiving chemotherapy with postmenopausal women without a history of cancer. Anxiety levels were also examined. METHODS: Data for this secondary analysis came from two studies. Global sleep quality and state anxiety were self-reported by 30 fatigued female breast cancer chemotherapy outpatients and 32 non-cancer postmenopausal women using Pittsburgh Sleep Quality Index (PSQI) and State-Trait Anxiety Inventory, respectively. RESULTS:Fatigued breast cancerpatients showed significant sleep difficulties, characterized by prolonged sleep onset latency (M=54.3, SD=49.2 min) and frequent nighttime awakenings, despite 40% of the patients using sleep medications three or more times a week. Compared to the non-cancer comparison group, fatigued patients reported significantly longer sleep latency (p=0.041), more use of sleep medications (p=0.006), and higher total PSQI scores (p=0.005). State anxiety levels did not differ between the two groups (p=0.88). CONCLUSIONS: Sleep is disrupted in fatigued breast cancerwomen undergoing chemotherapy. Nearly all fatigued patients (97%) had trouble sleeping (global PSQI scores>5), indicating significant difficulties in overall sleep quality among those patients. Knowledge of the nature of sleep disruption among cancerpatients may contribute to CRF symptom management leading to tailored interventions designed to improve sleep quality in cancerpatients thereby managing fatigue and improving quality of life.
Authors: Ann M Berger; Kathy P Parker; Stacey Young-McCaughan; Gail A Mallory; Andrea M Barsevick; Susan L Beck; Janet S Carpenter; Patricia A Carter; Lynne A Farr; Pamela S Hinds; Kathryn A Lee; Christine Miaskowski; Victoria Mock; Judith K Payne; Martica Hall Journal: Oncol Nurs Forum Date: 2005-11-03 Impact factor: 2.172
Authors: Nynke de Jong; Arnold D M Kester; Harry C Schouten; Huda Huijer Abu-Saad; Annemie M Courtens Journal: Cancer Nurs Date: 2006 Nov-Dec Impact factor: 2.592
Authors: Oxana Gronskaya Palesh; Kate Collie; Daniel Batiuchok; Jackie Tilston; Cheryl Koopman; Michael L Perlis; Lisa D Butler; Robert Carlson; David Spiegel Journal: Biol Psychol Date: 2006-12-12 Impact factor: 3.251
Authors: Joseph A Roscoe; Maralyn E Kaufman; Sara E Matteson-Rusby; Oxana G Palesh; Julie L Ryan; Sadhna Kohli; Michael L Perlis; Gary R Morrow Journal: Oncologist Date: 2007
Authors: Electra D Paskett; Catherine M Alfano; Mario A Davidson; Barbara L Andersen; Michelle J Naughton; Aurora Sherman; Paige Green McDonald; Jennifer Hays Journal: Cancer Date: 2008-12-01 Impact factor: 6.860
Authors: Julie L Otte; Janet S Carpenter; Shalini Manchanda; Kevin L Rand; Todd C Skaar; Michael Weaver; Yelena Chernyak; Xin Zhong; Christele Igega; Carol Landis Journal: Cancer Med Date: 2014-11-30 Impact factor: 4.452
Authors: Regina Claudia da Silva Souza; Maiara Rodrigues Dos Santos; Izabel Alves das Chagas Valota; Cristina Silva Sousa; Ana Lucia Siqueira Costa Calache Journal: Nurs Open Date: 2020-06-09